Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

GermanyBack to Germany

Clinical trials in Leer (ostfriesland)

9 clinical trials in Leer (ostfriesland), Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Leer (ostfriesland) at a glance
9
clinical trials
  • Not yet recruiting0
  • Paediatric trials0
  • Research sites0
Type of trial
Recruitment status
Quick filters

9 trials in Leer (ostfriesland)

Open in trial search

Colorectal cancer metastatic

Recruiting
Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Charite Universitaetsmedizin Berlin KöR

Hormone receptor positive breast cancer+1

Recruiting
Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Hormone receptor positive HER2 negative breast cancer

Recruiting
Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:European Organisation For Research And Treatment Of Cancer

DNA mismatch repair protein gene mutation+7

Not recruiting
Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:AIO-Studien gGmbH

Rectal cancer

Not recruiting
Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Goethe University Frankfurt

Rectal cancer

Not recruiting
Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Heidelberg University

Colon cancer stage II+1

Not recruiting
Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Technische Universitaet Dresden

Breast cancer+3

Not recruiting
Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:WSG Women's Cancer Study Group GmbH

Breast cancer

Not recruiting
Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Fulvestrant
  • Sponsor:Pfizer Inc.

Other cities in Germany

The busiest research cities in the country

All 515 cities in Germany

Clinical research in Leer (ostfriesland)

What the registry says about research in the country

01 Leer (ostfriesland)
Neoplasms — Breast Cancer
Clinical trial activity in Leer (Ostfriesland) includes several studies focused on breast cancer, especially HR+/HER2- early breast cancer, metastatic HR-positive, HER2-negative breast cancer, and advanced breast cancer. These trials are exploring new treatment options and strategies to improve long-term disease control, delay progression, and reduce the risk of recurrence. Testing new endocrine and targeted treatment approaches Evaluating ways to prevent or delay metastatic spread Comparing personalized therapy with standard care Assessing treatment effectiveness in high-risk disease Overall, the research aims to refine care for both early and advanced stages of breast cancer, with a strong focus on recurrence prevention and improved survival outcomes.
Neoplasms — Colorectal and Rectal Cancer
Another major area of research involves colorectal cancer and rectal cancer, including colon cancer stage II, locally advanced rectal cancer, intermediate and high-risk rectal cancer, and metastatic colorectal cancer. The studies are designed to improve disease-free survival, support organ preservation, and refine treatment choices after surgery or other definitive treatment. Studying adjuvant therapy after colon cancer surgery Exploring organ-preserving approaches in rectal cancer Evaluating post-treatment strategies for metastatic disease Improving outcomes in patients with high-risk colorectal cancer These trials reflect an active effort to make digestive system cancer treatment more effective while reducing the need for major surgery when possible.
Digestive System Diseases — Colorectal Cancer with Molecular Subtypes
Some studies focus on biologically defined groups within colorectal cancer, such as patients with MSI-high or MMR-deficient disease who cannot use oxaliplatin-based chemotherapy. This line of research is looking at whether newer approaches can improve outcomes in patients with specific tumor characteristics. Testing immunotherapy in high-risk colorectal cancer Targeting patients with limited standard treatment options Measuring disease-free survival after surgery Supporting treatment decisions based on tumor biology The goal is to expand effective treatment choices for harder-to-treat digestive tract cancers using more personalized strategies.
Neoplasms — Personalized Oncology
The trial portfolio in this city also highlights personalized oncology, with studies using markers such as ctDNA and tumor subtype to guide therapy choices. These trials are aimed at identifying who may benefit most from intensified treatment and who may safely avoid unnecessary therapy. Using biomarkers to guide adjuvant treatment Improving early detection of relapse risk Matching therapy intensity to individual risk Refining follow-up and recurrence prevention This research supports a more tailored approach to cancer care, with the aim of improving outcomes while limiting overtreatment.
Neoplasms — Advanced and Metastatic Disease Management
Several studies are investigating how best to manage advanced and metastatic cancer, especially in people whose disease has already spread or who have achieved only partial long-term control. The focus is on extending disease stability and improving the time before progression or death. Testing treatment continuation versus discontinuation strategies Comparing new therapies with established standards Maintaining stable disease for longer periods Supporting patients with advanced hormone receptor-positive disease These trials aim to improve quality and duration of disease control for patients living with metastatic breast cancer and metastatic colorectal cancer.
Digestive System Diseases — Rectal Cancer Organ Preservation
Research in rectal cancer is also centered on avoiding unnecessary radical surgery when possible. Trials are evaluating treatment pathways that may preserve the rectum while still maintaining strong cancer control, which could improve both recovery and quality of life. Assessing organ-preserving treatment approaches Studying local control after initial therapy Reducing the need for major surgery or stoma formation Balancing cancer control with function preservation This work is especially relevant for patients with locally advanced or high-risk rectal cancer, where treatment decisions can have a major impact on daily life.
Neoplasms — Targeted and Endocrine Therapies
Several ongoing studies are testing newer targeted therapies and endocrine treatments for hormone receptor-positive breast cancer. These trials are designed to compare emerging options with established therapies and to see whether they can better delay progression or recurrence. Evaluating novel hormone-based cancer treatments Comparing new agents with standard endocrine therapy Investigating resistance and relapse prevention Improving outcomes in advanced breast cancer In Germany, this work contributes to a broader effort to personalize breast cancer treatment based on disease behavior and prior therapy response.
Back to GermanyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.